Results 31 to 40 of about 53,113 (297)

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Liver Cancer, 2023
Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study.
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel   +10 more
doaj   +1 more source

Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab [PDF]

, 2017
Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and ...
Bazan, Viviana, Galvano, Antonio, Incorvaia, Lorena, Listì, Angela, Passiglia, Francesco, Rizzo, Sergio, Russo, Antonio   +6 more
core   +1 more source

Atezolizumab‐induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation

Respirology Case Reports, 2020
Atezolizumab is an immune checkpoint inhibitor (ICI) that is often associated with the development of several immune‐related adverse events, including fulminant type 1 diabetes mellitus (F1DM).
Toshihiko Nishioki, Motoyasu Kato, Shunichi Kataoka, Keita Miura, Tetsutaro Nagaoka, Kazuhisa Takahashi   +5 more
doaj   +1 more source

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

JTO Clinical and Research Reports
Introduction: Subcutaneous (SC) atezolizumab, a co-formulation containing atezolizumab and recombinant human hyaluronidase PH20), has been approved for use in more than 50 countries for the same indications as intravenous (IV) atezolizumab.
Federico Cappuzzo, MD, Zanete Zvirbule, MD, Ernesto Korbenfeld, MD, Jaroslaw Kolb-Sielecki, MD, Dolores Isla, MD, PhD, Aleksandra Szczesna, MD, PhD, Amparo Yovanna Castro Sanchez, PhD, Alberto Bustillos, MD, Xiaoyan Liu, PhD, Fiona Young, MbChB, Nadia Tosti, PhD, Marta Freitas Monteiro, MSc, PhD, Margarita Majem, MD, PhD   +12 more
doaj   +1 more source

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Frontiers in Drug Safety and Regulation, 2023
Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma.
Takahiro Niimura, Takahiro Niimura, Mitsuhiro Goda, Mitsuhiro Goda, Koji Miyata, Jun Matsumoto, Toshihiko Yoshioka, Toshihiko Yoshioka, Hirofumi Hamano, Hirofumi Hamano, Fuka Aizawa, Fuka Aizawa, Kenta Yagi, Kenta Yagi, Yuki Izawa-Ishizawa, Yuki Izawa-Ishizawa, Yoshito Zamami, Yoshito Zamami, Keisuke Ishizawa, Keisuke Ishizawa, Keisuke Ishizawa   +20 more
doaj   +1 more source

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC

JTO Clinical and Research Reports, 2020
Introduction: During treatment with immune checkpoint inhibitors, immune-related adverse events sometimes occur, and their management is a critical concern associated with such treatment.
Ryo Toyozawa, MD, Naoki Haratake, MD, PhD, Gouji Toyokawa, MD, PhD, Taichi Matsubara, MD, PhD, Shinkichi Takamori, MD, PhD, Naoko Miura, MD, PhD, Masafumi Yamaguchi, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Takashi Seto, MD, PhD   +8 more
doaj   +1 more source

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Frontiers in Oncology, 2018
Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease progression.
Rachel Ryu, Kristina E. Ward
doaj   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source